LIFE BioCEEd, a leading healthtech investment company, is proud to announce the signing of a Memorandum of Cooperation with Charles University Innovations Prague (CUIP), the innovation subsidiary of Charles University. This strategic partnership is aimed at fostering the transfer of technologies across a wide range of biomedical, pharmaceutical, and healthcare disciplines. LIFE BioCEEd has allocated CZK 500 million in capital to invest in these transformative projects.
The memorandum was signed by Stefan Savic, CEO of LIFE BioCEEd, and Otomar Sláma, Chairman of the Board of Directors at CUIP. The agreement focuses on supporting the development of new drugs, diagnostics, and medical devices. LIFE BioCEEd specializes in funding and accelerating early-stage healthcare projects and facilitating their successful transition from academic research to market-ready solutions.
“Our mission is to invest in projects that address pressing global healthcare challenges, including immune diseases, mental health, fertility, pain management, and aging-related conditions,” said Stefan Savic, CEO of LIFE BioCEEd. “This collaboration strengthens our ability to bridge the gap between innovative research and commercialization, ultimately bringing impactful solutions to patients who need them most.”
Through this partnership, LIFE BioCEEd will gain access to Charles University’s portfolio of promising biomedical and healthcare research projects, including biopharmaceutical and diagnostic innovations. CUIP will play a pivotal role in identifying high-potential projects and ensuring seamless collaboration between academic research teams and LIFE BioCEEd’s experts.
“By working together with CUIP, we aim to unlock the commercialization potential of groundbreaking scientific projects and provide critical funding to research teams during the proof-of-concept stage,” Savic added. “This partnership allows us to provide not only financial support but also expert guidance in bringing innovative ideas to the market.”
LIFE BioCEEd’s investment focus spans a broad range of medical fields, including cardiology, endocrinology, neurology, oncology, immunology, radiology, mental health, hematology, gynecology, geriatrics, and gastroenterology. With CZK 500 million in dedicated capital, the company is committed to supporting researchers whose projects demonstrate strong potential for real-world application and delivering innovative healthcare solutions to patients worldwide.
This collaboration marks an important step in transforming healthcare through innovation, strengthening ties between academic research and the commercial sector, and ensuring that groundbreaking discoveries reach their full potential to benefit society.